Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCOVERY: Pegcetacoplan in Glomerulopathies
NCT03453619Phase 2Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Apr 2020
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pegcetacoplan in IgA nephropathy (IgAN), lupus nephritis (LN), primary membranous nephropathy (PMN), Complement 3 glomerulopathy (C3G), C3 glomerulonephritis (C3GN), sponsored by Apellis Pharmaceuticals. Started Feb 2018; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
IgA nephropathy (IgAN)lupus nephritis (LN)primary membranous nephropathy (PMN)Complement 3 glomerulopathy (C3G)C3 glomerulonephritis (C3GN)
Beyond the preview
Go deeper on NCT03453619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03453619.